Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. (FOLD) Stock Competitors & Peer Comparison
See (FOLD) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| FOLD | $7.52 | +0.53% | 2.3B | -62.67 | -$0.12 | N/A |
| VRTX | $387.18 | -0.45% | 99.2B | 27.51 | $14.07 | N/A |
| REGN | $587.65 | +2.67% | 61.2B | 14.81 | $39.67 | +0.45% |
| ALNY | $451.20 | +1.70% | 59.1B | -184.16 | -$2.45 | N/A |
| ARGX | $708.09 | +4.54% | 43.3B | 36.00 | $19.67 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| BNTX | $104.79 | -0.27% | 25.2B | -63.13 | -$1.66 | N/A |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| SMMT | $26.98 | +2.70% | 20B | -26.71 | -$1.01 | N/A |
| DNA-WT | $0.27 | -2.76% | 18.7B | N/A | N/A | N/A |
Stock Comparison
FOLD vs VRTX Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, VRTX has a market cap of 99.2B. Regarding current trading prices, FOLD is priced at $7.52, while VRTX trades at $387.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas VRTX's P/E ratio is 27.51. In terms of profitability, FOLD's ROE is -0.20%, compared to VRTX's ROE of +0.22%. Regarding short-term risk, FOLD is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check VRTX's competition here
FOLD vs REGN Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, REGN has a market cap of 61.2B. Regarding current trading prices, FOLD is priced at $7.52, while REGN trades at $587.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas REGN's P/E ratio is 14.81. In terms of profitability, FOLD's ROE is -0.20%, compared to REGN's ROE of +0.15%. Regarding short-term risk, FOLD is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check REGN's competition here
FOLD vs ALNY Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, ALNY has a market cap of 59.1B. Regarding current trading prices, FOLD is priced at $7.52, while ALNY trades at $451.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas ALNY's P/E ratio is -184.16. In terms of profitability, FOLD's ROE is -0.20%, compared to ALNY's ROE of -2.74%. Regarding short-term risk, FOLD is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check ALNY's competition here
FOLD vs ARGX Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, ARGX has a market cap of 43.3B. Regarding current trading prices, FOLD is priced at $7.52, while ARGX trades at $708.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas ARGX's P/E ratio is 36.00. In terms of profitability, FOLD's ROE is -0.20%, compared to ARGX's ROE of +0.26%. Regarding short-term risk, FOLD is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check ARGX's competition here
FOLD vs SGEN Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, FOLD is priced at $7.52, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas SGEN's P/E ratio is -57.19. In terms of profitability, FOLD's ROE is -0.20%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, FOLD is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check SGEN's competition here
FOLD vs BNTX Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, BNTX has a market cap of 25.2B. Regarding current trading prices, FOLD is priced at $7.52, while BNTX trades at $104.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas BNTX's P/E ratio is -63.13. In terms of profitability, FOLD's ROE is -0.20%, compared to BNTX's ROE of -0.02%. Regarding short-term risk, FOLD is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check BNTX's competition here
FOLD vs BGNE Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, FOLD is priced at $7.52, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas BGNE's P/E ratio is -22.55. In terms of profitability, FOLD's ROE is -0.20%, compared to BGNE's ROE of -0.05%. Regarding short-term risk, FOLD is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check BGNE's competition here
FOLD vs SMMT Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, SMMT has a market cap of 20B. Regarding current trading prices, FOLD is priced at $7.52, while SMMT trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas SMMT's P/E ratio is -26.71. In terms of profitability, FOLD's ROE is -0.20%, compared to SMMT's ROE of -2.09%. Regarding short-term risk, FOLD is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check SMMT's competition here
FOLD vs DNA-WT Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, FOLD is priced at $7.52, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, FOLD's ROE is -0.20%, compared to DNA-WT's ROE of -0.45%. Regarding short-term risk, FOLD is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check DNA-WT's competition here
FOLD vs INCY Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, INCY has a market cap of 16.4B. Regarding current trading prices, FOLD is priced at $7.52, while INCY trades at $84.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas INCY's P/E ratio is 19.86. In terms of profitability, FOLD's ROE is -0.20%, compared to INCY's ROE of +0.24%. Regarding short-term risk, FOLD is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check INCY's competition here
FOLD vs RPRX Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, RPRX has a market cap of 15.6B. Regarding current trading prices, FOLD is priced at $7.52, while RPRX trades at $35.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas RPRX's P/E ratio is 15.71. In terms of profitability, FOLD's ROE is -0.20%, compared to RPRX's ROE of +0.15%. Regarding short-term risk, FOLD is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check RPRX's competition here
FOLD vs GMAB Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, GMAB has a market cap of 15.5B. Regarding current trading prices, FOLD is priced at $7.52, while GMAB trades at $24.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas GMAB's P/E ratio is 12.72. In terms of profitability, FOLD's ROE is -0.20%, compared to GMAB's ROE of +0.28%. Regarding short-term risk, FOLD is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check GMAB's competition here
FOLD vs UTHR Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, UTHR has a market cap of 14B. Regarding current trading prices, FOLD is priced at $7.52, while UTHR trades at $309.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas UTHR's P/E ratio is 12.06. In terms of profitability, FOLD's ROE is -0.20%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, FOLD is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check UTHR's competition here
FOLD vs KRTX Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, FOLD is priced at $7.52, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas KRTX's P/E ratio is -28.09. In terms of profitability, FOLD's ROE is -0.20%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, FOLD is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check KRTX's competition here
FOLD vs ASND Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, ASND has a market cap of 11.9B. Regarding current trading prices, FOLD is priced at $7.52, while ASND trades at $196.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas ASND's P/E ratio is -36.90. In terms of profitability, FOLD's ROE is -0.20%, compared to ASND's ROE of +1.52%. Regarding short-term risk, FOLD is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check ASND's competition here
FOLD vs BMRN Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, BMRN has a market cap of 11B. Regarding current trading prices, FOLD is priced at $7.52, while BMRN trades at $57.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas BMRN's P/E ratio is 16.95. In terms of profitability, FOLD's ROE is -0.20%, compared to BMRN's ROE of +0.11%. Regarding short-term risk, FOLD is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check BMRN's competition here
FOLD vs EXEL Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, EXEL has a market cap of 10.3B. Regarding current trading prices, FOLD is priced at $7.52, while EXEL trades at $38.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas EXEL's P/E ratio is 18.43. In terms of profitability, FOLD's ROE is -0.20%, compared to EXEL's ROE of +0.28%. Regarding short-term risk, FOLD is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check EXEL's competition here
FOLD vs MRNA Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, MRNA has a market cap of 9.6B. Regarding current trading prices, FOLD is priced at $7.52, while MRNA trades at $24.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas MRNA's P/E ratio is -3.29. In terms of profitability, FOLD's ROE is -0.20%, compared to MRNA's ROE of -0.27%. Regarding short-term risk, FOLD is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check MRNA's competition here
FOLD vs RXDX Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, FOLD is priced at $7.52, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas RXDX's P/E ratio is -56.47. In terms of profitability, FOLD's ROE is -0.20%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, FOLD is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check RXDX's competition here
FOLD vs MDGL Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, MDGL has a market cap of 9.5B. Regarding current trading prices, FOLD is priced at $7.52, while MDGL trades at $424.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas MDGL's P/E ratio is -33.60. In terms of profitability, FOLD's ROE is -0.20%, compared to MDGL's ROE of -0.38%. Regarding short-term risk, FOLD is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check MDGL's competition here
FOLD vs BBIO Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, BBIO has a market cap of 9.3B. Regarding current trading prices, FOLD is priced at $7.52, while BBIO trades at $48.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas BBIO's P/E ratio is -11.83. In terms of profitability, FOLD's ROE is -0.20%, compared to BBIO's ROE of +0.51%. Regarding short-term risk, FOLD is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check BBIO's competition here
FOLD vs VRNA Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, VRNA has a market cap of 9B. Regarding current trading prices, FOLD is priced at $7.52, while VRNA trades at $105.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas VRNA's P/E ratio is -100.64. In terms of profitability, FOLD's ROE is -0.20%, compared to VRNA's ROE of -0.39%. Regarding short-term risk, FOLD is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check VRNA's competition here
FOLD vs TECH Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, TECH has a market cap of 8.9B. Regarding current trading prices, FOLD is priced at $7.52, while TECH trades at $56.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas TECH's P/E ratio is 123.46. In terms of profitability, FOLD's ROE is -0.20%, compared to TECH's ROE of +0.06%. Regarding short-term risk, FOLD is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check TECH's competition here
FOLD vs IMGN Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, FOLD is priced at $7.52, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas IMGN's P/E ratio is -111.55. In terms of profitability, FOLD's ROE is -0.20%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, FOLD is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check IMGN's competition here
FOLD vs HALO Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, HALO has a market cap of 8.5B. Regarding current trading prices, FOLD is priced at $7.52, while HALO trades at $72.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas HALO's P/E ratio is 16.69. In terms of profitability, FOLD's ROE is -0.20%, compared to HALO's ROE of +1.37%. Regarding short-term risk, FOLD is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check HALO's competition here
FOLD vs BPMC Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, FOLD is priced at $7.52, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas BPMC's P/E ratio is -51.58. In terms of profitability, FOLD's ROE is -0.20%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, FOLD is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check BPMC's competition here
FOLD vs CERE Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, FOLD is priced at $7.52, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas CERE's P/E ratio is -16.47. In terms of profitability, FOLD's ROE is -0.20%, compared to CERE's ROE of -0.72%. Regarding short-term risk, FOLD is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check CERE's competition here
FOLD vs ROIV Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, ROIV has a market cap of 8.1B. Regarding current trading prices, FOLD is priced at $7.52, while ROIV trades at $11.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas ROIV's P/E ratio is -10.86. In terms of profitability, FOLD's ROE is -0.20%, compared to ROIV's ROE of -0.10%. Regarding short-term risk, FOLD is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check ROIV's competition here
FOLD vs ROIVW Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, FOLD is priced at $7.52, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, FOLD's ROE is -0.20%, compared to ROIVW's ROE of -0.10%. Regarding short-term risk, FOLD is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check ROIVW's competition here
FOLD vs JAZZ Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, JAZZ has a market cap of 7.6B. Regarding current trading prices, FOLD is priced at $7.52, while JAZZ trades at $125.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas JAZZ's P/E ratio is -17.91. In terms of profitability, FOLD's ROE is -0.20%, compared to JAZZ's ROE of -0.10%. Regarding short-term risk, FOLD is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check JAZZ's competition here
FOLD vs CORT Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, CORT has a market cap of 7.3B. Regarding current trading prices, FOLD is priced at $7.52, while CORT trades at $69.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas CORT's P/E ratio is 62.12. In terms of profitability, FOLD's ROE is -0.20%, compared to CORT's ROE of +0.20%. Regarding short-term risk, FOLD is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check CORT's competition here
FOLD vs RVMD Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, RVMD has a market cap of 7B. Regarding current trading prices, FOLD is priced at $7.52, while RVMD trades at $37.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas RVMD's P/E ratio is -8.25. In terms of profitability, FOLD's ROE is -0.20%, compared to RVMD's ROE of -0.42%. Regarding short-term risk, FOLD is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check RVMD's competition here
FOLD vs RYTM Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, RYTM has a market cap of 6.7B. Regarding current trading prices, FOLD is priced at $7.52, while RYTM trades at $101.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas RYTM's P/E ratio is -33.62. In terms of profitability, FOLD's ROE is -0.20%, compared to RYTM's ROE of -1.19%. Regarding short-term risk, FOLD is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check RYTM's competition here
FOLD vs IONS Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, IONS has a market cap of 6.7B. Regarding current trading prices, FOLD is priced at $7.52, while IONS trades at $42.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas IONS's P/E ratio is -23.96. In terms of profitability, FOLD's ROE is -0.20%, compared to IONS's ROE of -0.45%. Regarding short-term risk, FOLD is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check IONS's competition here
FOLD vs RETA Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, FOLD is priced at $7.52, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas RETA's P/E ratio is -66.29. In terms of profitability, FOLD's ROE is -0.20%, compared to RETA's ROE of +0.47%. Regarding short-term risk, FOLD is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check RETA's competition here
FOLD vs RNA Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, RNA has a market cap of 6.1B. Regarding current trading prices, FOLD is priced at $7.52, while RNA trades at $47.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas RNA's P/E ratio is -13.22. In terms of profitability, FOLD's ROE is -0.20%, compared to RNA's ROE of -0.33%. Regarding short-term risk, FOLD is less volatile compared to RNA. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check RNA's competition here
FOLD vs AXSM Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, AXSM has a market cap of 6B. Regarding current trading prices, FOLD is priced at $7.52, while AXSM trades at $121.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas AXSM's P/E ratio is -23.94. In terms of profitability, FOLD's ROE is -0.20%, compared to AXSM's ROE of -3.58%. Regarding short-term risk, FOLD is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check AXSM's competition here
FOLD vs ABVX Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, ABVX has a market cap of 6B. Regarding current trading prices, FOLD is priced at $7.52, while ABVX trades at $79.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas ABVX's P/E ratio is -23.10. In terms of profitability, FOLD's ROE is -0.20%, compared to ABVX's ROE of -1.62%. Regarding short-term risk, FOLD is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check ABVX's competition here
FOLD vs ABCM Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, FOLD is priced at $7.52, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, FOLD's ROE is -0.20%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, FOLD is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check ABCM's competition here
FOLD vs ISEE Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, FOLD is priced at $7.52, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas ISEE's P/E ratio is -22.44. In terms of profitability, FOLD's ROE is -0.20%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, FOLD is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check ISEE's competition here
FOLD vs NUVL Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, NUVL has a market cap of 5.4B. Regarding current trading prices, FOLD is priced at $7.52, while NUVL trades at $74.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas NUVL's P/E ratio is -15.23. In terms of profitability, FOLD's ROE is -0.20%, compared to NUVL's ROE of -0.33%. Regarding short-term risk, FOLD is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check NUVL's competition here
FOLD vs MRUS Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, MRUS has a market cap of 5.1B. Regarding current trading prices, FOLD is priced at $7.52, while MRUS trades at $66.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas MRUS's P/E ratio is -12.29. In terms of profitability, FOLD's ROE is -0.20%, compared to MRUS's ROE of -0.55%. Regarding short-term risk, FOLD is less volatile compared to MRUS. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check MRUS's competition here
FOLD vs CRSP Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, CRSP has a market cap of 5B. Regarding current trading prices, FOLD is priced at $7.52, while CRSP trades at $54.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas CRSP's P/E ratio is -10.16. In terms of profitability, FOLD's ROE is -0.20%, compared to CRSP's ROE of -0.25%. Regarding short-term risk, FOLD is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check CRSP's competition here
FOLD vs ALKS Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, ALKS has a market cap of 4.8B. Regarding current trading prices, FOLD is priced at $7.52, while ALKS trades at $28.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas ALKS's P/E ratio is 14.00. In terms of profitability, FOLD's ROE is -0.20%, compared to ALKS's ROE of +0.24%. Regarding short-term risk, FOLD is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check ALKS's competition here
FOLD vs CYTK Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, CYTK has a market cap of 4.6B. Regarding current trading prices, FOLD is priced at $7.52, while CYTK trades at $38.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas CYTK's P/E ratio is -7.46. In terms of profitability, FOLD's ROE is -0.20%, compared to CYTK's ROE of +3.09%. Regarding short-term risk, FOLD is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check CYTK's competition here
FOLD vs TGTX Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, TGTX has a market cap of 4.5B. Regarding current trading prices, FOLD is priced at $7.52, while TGTX trades at $28.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas TGTX's P/E ratio is 74.42. In terms of profitability, FOLD's ROE is -0.20%, compared to TGTX's ROE of +0.29%. Regarding short-term risk, FOLD is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check TGTX's competition here
FOLD vs ALPN Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, FOLD is priced at $7.52, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas ALPN's P/E ratio is -101.52. In terms of profitability, FOLD's ROE is -0.20%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, FOLD is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check ALPN's competition here
FOLD vs ACAD Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, ACAD has a market cap of 4.3B. Regarding current trading prices, FOLD is priced at $7.52, while ACAD trades at $25.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas ACAD's P/E ratio is 19.34. In terms of profitability, FOLD's ROE is -0.20%, compared to ACAD's ROE of +0.31%. Regarding short-term risk, FOLD is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check ACAD's competition here
FOLD vs KRYS Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, KRYS has a market cap of 4.3B. Regarding current trading prices, FOLD is priced at $7.52, while KRYS trades at $146.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas KRYS's P/E ratio is 29.85. In terms of profitability, FOLD's ROE is -0.20%, compared to KRYS's ROE of +0.15%. Regarding short-term risk, FOLD is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check KRYS's competition here
FOLD vs TLX Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, TLX has a market cap of 4.2B. Regarding current trading prices, FOLD is priced at $7.52, while TLX trades at $12.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas TLX's P/E ratio is 627.00. In terms of profitability, FOLD's ROE is -0.20%, compared to TLX's ROE of +0.10%. Regarding short-term risk, FOLD is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check TLX's competition here
FOLD vs OPT Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, FOLD is priced at $7.52, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas OPT's P/E ratio is -1.52. In terms of profitability, FOLD's ROE is -0.20%, compared to OPT's ROE of +2.60%. Regarding short-term risk, FOLD is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check OPT's competition here
FOLD vs MRTX Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, FOLD is priced at $7.52, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas MRTX's P/E ratio is -4.82. In terms of profitability, FOLD's ROE is -0.20%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, FOLD is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check MRTX's competition here
FOLD vs ADMA Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, ADMA has a market cap of 4.1B. Regarding current trading prices, FOLD is priced at $7.52, while ADMA trades at $17.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas ADMA's P/E ratio is 21.11. In terms of profitability, FOLD's ROE is -0.20%, compared to ADMA's ROE of +0.62%. Regarding short-term risk, FOLD is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check ADMA's competition here
FOLD vs AAPG Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, AAPG has a market cap of 3.9B. Regarding current trading prices, FOLD is priced at $7.52, while AAPG trades at $42.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas AAPG's P/E ratio is -21.11. In terms of profitability, FOLD's ROE is -0.20%, compared to AAPG's ROE of -0.79%. Regarding short-term risk, FOLD is less volatile compared to AAPG. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check AAPG's competition here
FOLD vs PTCT Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, PTCT has a market cap of 3.9B. Regarding current trading prices, FOLD is priced at $7.52, while PTCT trades at $49.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas PTCT's P/E ratio is 7.02. In terms of profitability, FOLD's ROE is -0.20%, compared to PTCT's ROE of -0.99%. Regarding short-term risk, FOLD is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check PTCT's competition here
FOLD vs PCVX Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, PCVX has a market cap of 3.9B. Regarding current trading prices, FOLD is priced at $7.52, while PCVX trades at $30.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas PCVX's P/E ratio is -7.36. In terms of profitability, FOLD's ROE is -0.20%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, FOLD is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check PCVX's competition here
FOLD vs ACLX Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, ACLX has a market cap of 3.9B. Regarding current trading prices, FOLD is priced at $7.52, while ACLX trades at $69.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas ACLX's P/E ratio is -20.50. In terms of profitability, FOLD's ROE is -0.20%, compared to ACLX's ROE of -0.43%. Regarding short-term risk, FOLD is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check ACLX's competition here
FOLD vs AKRO Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, AKRO has a market cap of 3.8B. Regarding current trading prices, FOLD is priced at $7.52, while AKRO trades at $48.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas AKRO's P/E ratio is -12.63. In terms of profitability, FOLD's ROE is -0.20%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, FOLD is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check AKRO's competition here
FOLD vs ZLAB Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, ZLAB has a market cap of 3.8B. Regarding current trading prices, FOLD is priced at $7.52, while ZLAB trades at $34.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas ZLAB's P/E ratio is -17.14. In terms of profitability, FOLD's ROE is -0.20%, compared to ZLAB's ROE of -0.27%. Regarding short-term risk, FOLD is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check ZLAB's competition here
FOLD vs RYZB Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, FOLD is priced at $7.52, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas RYZB's P/E ratio is -57.86. In terms of profitability, FOLD's ROE is -0.20%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, FOLD is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check RYZB's competition here
FOLD vs CBAY Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, FOLD is priced at $7.52, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas CBAY's P/E ratio is -32.81. In terms of profitability, FOLD's ROE is -0.20%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, FOLD is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check CBAY's competition here
FOLD vs MIRM Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, MIRM has a market cap of 3.7B. Regarding current trading prices, FOLD is priced at $7.52, while MIRM trades at $74.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas MIRM's P/E ratio is -61.32. In terms of profitability, FOLD's ROE is -0.20%, compared to MIRM's ROE of -0.25%. Regarding short-term risk, FOLD is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check MIRM's competition here
FOLD vs SLNO Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, SLNO has a market cap of 3.7B. Regarding current trading prices, FOLD is priced at $7.52, while SLNO trades at $69.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas SLNO's P/E ratio is -16.50. In terms of profitability, FOLD's ROE is -0.20%, compared to SLNO's ROE of -0.74%. Regarding short-term risk, FOLD is less volatile compared to SLNO. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check SLNO's competition here
FOLD vs PTGX Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, PTGX has a market cap of 3.5B. Regarding current trading prices, FOLD is priced at $7.52, while PTGX trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas PTGX's P/E ratio is 78.07. In terms of profitability, FOLD's ROE is -0.20%, compared to PTGX's ROE of +0.08%. Regarding short-term risk, FOLD is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check PTGX's competition here
FOLD vs SWTX Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, FOLD is priced at $7.52, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas SWTX's P/E ratio is -13.78. In terms of profitability, FOLD's ROE is -0.20%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, FOLD is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check SWTX's competition here
FOLD vs APLS Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, APLS has a market cap of 3.5B. Regarding current trading prices, FOLD is priced at $7.52, while APLS trades at $27.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas APLS's P/E ratio is -15.26. In terms of profitability, FOLD's ROE is -0.20%, compared to APLS's ROE of -1.16%. Regarding short-term risk, FOLD is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check APLS's competition here
FOLD vs MTSR Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, MTSR has a market cap of 3.5B. Regarding current trading prices, FOLD is priced at $7.52, while MTSR trades at $33.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas MTSR's P/E ratio is -11.33. In terms of profitability, FOLD's ROE is -0.20%, compared to MTSR's ROE of -0.90%. Regarding short-term risk, FOLD is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check MTSR's competition here
FOLD vs MLTX Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, MLTX has a market cap of 3.5B. Regarding current trading prices, FOLD is priced at $7.52, while MLTX trades at $54.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas MLTX's P/E ratio is -19.53. In terms of profitability, FOLD's ROE is -0.20%, compared to MLTX's ROE of -0.42%. Regarding short-term risk, FOLD is less volatile compared to MLTX. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check MLTX's competition here
FOLD vs SRRK Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, SRRK has a market cap of 3.2B. Regarding current trading prices, FOLD is priced at $7.52, while SRRK trades at $33.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas SRRK's P/E ratio is -12.33. In terms of profitability, FOLD's ROE is -0.20%, compared to SRRK's ROE of -1.27%. Regarding short-term risk, FOLD is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check SRRK's competition here
FOLD vs LEGN Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, LEGN has a market cap of 3.2B. Regarding current trading prices, FOLD is priced at $7.52, while LEGN trades at $35.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas LEGN's P/E ratio is -19.71. In terms of profitability, FOLD's ROE is -0.20%, compared to LEGN's ROE of -0.31%. Regarding short-term risk, FOLD is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check LEGN's competition here
FOLD vs KYMR Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, KYMR has a market cap of 3.1B. Regarding current trading prices, FOLD is priced at $7.52, while KYMR trades at $43.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas KYMR's P/E ratio is -12.57. In terms of profitability, FOLD's ROE is -0.20%, compared to KYMR's ROE of -0.32%. Regarding short-term risk, FOLD is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check KYMR's competition here
FOLD vs LGND Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, LGND has a market cap of 3.1B. Regarding current trading prices, FOLD is priced at $7.52, while LGND trades at $159.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas LGND's P/E ratio is -39.64. In terms of profitability, FOLD's ROE is -0.20%, compared to LGND's ROE of -0.09%. Regarding short-term risk, FOLD is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check LGND's competition here
FOLD vs XENE Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, XENE has a market cap of 3B. Regarding current trading prices, FOLD is priced at $7.52, while XENE trades at $38.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas XENE's P/E ratio is -10.89. In terms of profitability, FOLD's ROE is -0.20%, compared to XENE's ROE of -0.39%. Regarding short-term risk, FOLD is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check XENE's competition here
FOLD vs ARWR Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, ARWR has a market cap of 2.9B. Regarding current trading prices, FOLD is priced at $7.52, while ARWR trades at $21.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas ARWR's P/E ratio is -17.65. In terms of profitability, FOLD's ROE is -0.20%, compared to ARWR's ROE of -0.41%. Regarding short-term risk, FOLD is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check ARWR's competition here
FOLD vs VKTX Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, VKTX has a market cap of 2.9B. Regarding current trading prices, FOLD is priced at $7.52, while VKTX trades at $26.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas VKTX's P/E ratio is -16.91. In terms of profitability, FOLD's ROE is -0.20%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, FOLD is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check VKTX's competition here
FOLD vs CRNX Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, CRNX has a market cap of 2.9B. Regarding current trading prices, FOLD is priced at $7.52, while CRNX trades at $30.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas CRNX's P/E ratio is -7.54. In terms of profitability, FOLD's ROE is -0.20%, compared to CRNX's ROE of -0.32%. Regarding short-term risk, FOLD is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check CRNX's competition here
FOLD vs MORF Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, FOLD is priced at $7.52, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas MORF's P/E ratio is -14.88. In terms of profitability, FOLD's ROE is -0.20%, compared to MORF's ROE of -0.16%. Regarding short-term risk, FOLD is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check MORF's competition here
FOLD vs MOR Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, FOLD is priced at $7.52, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas MOR's P/E ratio is -12.64. In terms of profitability, FOLD's ROE is -0.20%, compared to MOR's ROE of -1.84%. Regarding short-term risk, FOLD is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check MOR's competition here
FOLD vs RARE Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, RARE has a market cap of 2.8B. Regarding current trading prices, FOLD is priced at $7.52, while RARE trades at $29.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas RARE's P/E ratio is -5.39. In terms of profitability, FOLD's ROE is -0.20%, compared to RARE's ROE of -2.37%. Regarding short-term risk, FOLD is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check RARE's competition here
FOLD vs NAMS Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, NAMS has a market cap of 2.8B. Regarding current trading prices, FOLD is priced at $7.52, while NAMS trades at $25.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas NAMS's P/E ratio is -15.84. In terms of profitability, FOLD's ROE is -0.20%, compared to NAMS's ROE of -0.25%. Regarding short-term risk, FOLD is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check NAMS's competition here
FOLD vs KDNY Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, FOLD is priced at $7.52, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas KDNY's P/E ratio is -12.47. In terms of profitability, FOLD's ROE is -0.20%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, FOLD is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check KDNY's competition here
FOLD vs IMVT Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, IMVT has a market cap of 2.6B. Regarding current trading prices, FOLD is priced at $7.52, while IMVT trades at $15.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas IMVT's P/E ratio is -5.31. In terms of profitability, FOLD's ROE is -0.20%, compared to IMVT's ROE of -0.84%. Regarding short-term risk, FOLD is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check IMVT's competition here
FOLD vs MYOV Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, FOLD is priced at $7.52, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas MYOV's P/E ratio is -14.05. In terms of profitability, FOLD's ROE is -0.20%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, FOLD is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check MYOV's competition here
FOLD vs KNSA Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, KNSA has a market cap of 2.5B. Regarding current trading prices, FOLD is priced at $7.52, while KNSA trades at $33.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas KNSA's P/E ratio is 671.40. In terms of profitability, FOLD's ROE is -0.20%, compared to KNSA's ROE of +0.01%. Regarding short-term risk, FOLD is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check KNSA's competition here
FOLD vs TARS Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, TARS has a market cap of 2.5B. Regarding current trading prices, FOLD is priced at $7.52, while TARS trades at $58.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas TARS's P/E ratio is -25.70. In terms of profitability, FOLD's ROE is -0.20%, compared to TARS's ROE of -0.32%. Regarding short-term risk, FOLD is less volatile compared to TARS. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check TARS's competition here
FOLD vs CPRX Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, CPRX has a market cap of 2.4B. Regarding current trading prices, FOLD is priced at $7.52, while CPRX trades at $19.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas CPRX's P/E ratio is 12.08. In terms of profitability, FOLD's ROE is -0.20%, compared to CPRX's ROE of +0.27%. Regarding short-term risk, FOLD is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check CPRX's competition here
FOLD vs LQDA Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, LQDA has a market cap of 2.4B. Regarding current trading prices, FOLD is priced at $7.52, while LQDA trades at $27.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas LQDA's P/E ratio is -15.24. In terms of profitability, FOLD's ROE is -0.20%, compared to LQDA's ROE of -1.58%. Regarding short-term risk, FOLD is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check LQDA's competition here
FOLD vs PRVB Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, FOLD is priced at $7.52, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas PRVB's P/E ratio is -16.43. In terms of profitability, FOLD's ROE is -0.20%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, FOLD is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check PRVB's competition here
FOLD vs LBPH Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, FOLD is priced at $7.52, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas LBPH's P/E ratio is -26.66. In terms of profitability, FOLD's ROE is -0.20%, compared to LBPH's ROE of -0.21%. Regarding short-term risk, FOLD is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check LBPH's competition here
FOLD vs VCYT Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, VCYT has a market cap of 2.3B. Regarding current trading prices, FOLD is priced at $7.52, while VCYT trades at $29.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas VCYT's P/E ratio is 85.50. In terms of profitability, FOLD's ROE is -0.20%, compared to VCYT's ROE of +0.02%. Regarding short-term risk, FOLD is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check VCYT's competition here
FOLD vs DNLI Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, DNLI has a market cap of 2.3B. Regarding current trading prices, FOLD is priced at $7.52, while DNLI trades at $15.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas DNLI's P/E ratio is -5.53. In terms of profitability, FOLD's ROE is -0.20%, compared to DNLI's ROE of -0.41%. Regarding short-term risk, FOLD is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check DNLI's competition here
FOLD vs DICE Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, FOLD is priced at $7.52, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas DICE's P/E ratio is -21.91. In terms of profitability, FOLD's ROE is -0.20%, compared to DICE's ROE of +0.56%. Regarding short-term risk, FOLD is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for FOLD.Check DICE's competition here
FOLD vs IBRX Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, IBRX has a market cap of 2.2B. Regarding current trading prices, FOLD is priced at $7.52, while IBRX trades at $2.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas IBRX's P/E ratio is -5.06. In terms of profitability, FOLD's ROE is -0.20%, compared to IBRX's ROE of +0.61%. Regarding short-term risk, FOLD is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check IBRX's competition here
FOLD vs CNTA Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, CNTA has a market cap of 2.2B. Regarding current trading prices, FOLD is priced at $7.52, while CNTA trades at $16.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas CNTA's P/E ratio is -9.08. In terms of profitability, FOLD's ROE is -0.20%, compared to CNTA's ROE of -0.56%. Regarding short-term risk, FOLD is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check CNTA's competition here
FOLD vs AGIO Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, AGIO has a market cap of 2.2B. Regarding current trading prices, FOLD is priced at $7.52, while AGIO trades at $38.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas AGIO's P/E ratio is 3.41. In terms of profitability, FOLD's ROE is -0.20%, compared to AGIO's ROE of +0.43%. Regarding short-term risk, FOLD is less volatile compared to AGIO. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check AGIO's competition here
FOLD vs APGE Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, APGE has a market cap of 2.2B. Regarding current trading prices, FOLD is priced at $7.52, while APGE trades at $37.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas APGE's P/E ratio is -9.15. In terms of profitability, FOLD's ROE is -0.20%, compared to APGE's ROE of -0.23%. Regarding short-term risk, FOLD is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check APGE's competition here
FOLD vs IDYA Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, IDYA has a market cap of 2.2B. Regarding current trading prices, FOLD is priced at $7.52, while IDYA trades at $24.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas IDYA's P/E ratio is -6.58. In terms of profitability, FOLD's ROE is -0.20%, compared to IDYA's ROE of -0.31%. Regarding short-term risk, FOLD is less volatile compared to IDYA. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check IDYA's competition here
FOLD vs CALT Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, FOLD is priced at $7.52, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas CALT's P/E ratio is -22.73. In terms of profitability, FOLD's ROE is -0.20%, compared to CALT's ROE of -1.67%. Regarding short-term risk, FOLD is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check CALT's competition here
FOLD vs OCUL Comparison August 2025
FOLD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FOLD stands at 2.3B. In comparison, OCUL has a market cap of 2.1B. Regarding current trading prices, FOLD is priced at $7.52, while OCUL trades at $12.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FOLD currently has a P/E ratio of -62.67, whereas OCUL's P/E ratio is -9.77. In terms of profitability, FOLD's ROE is -0.20%, compared to OCUL's ROE of -0.70%. Regarding short-term risk, FOLD is less volatile compared to OCUL. This indicates potentially lower risk in terms of short-term price fluctuations for FOLD.Check OCUL's competition here